Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 10/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.38 |
| ▸ | ARG1 | P05089 | 1/20 | 0.37 |
| ▸ | ARG2 | P78540 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12443041 | 0.84 | POLB (0.47) | POLBS1PR5S1PR1PIK3CDS1PR3 | |
| SCHEMBL30479891 | 0.83 | POLB (0.42) | POLBS1PR5S1PR1MAPTS1PR3 | |
| SCHEMBL12000479 | 0.83 | PIK3CD (0.48) | POLBS1PR5S1PR1PIK3CDARG1 | |
| SCHEMBL23557645 | 0.81 | KMT2A (0.51) | POLB | |
| SCHEMBL21047360 | 0.81 | KMT2A (0.51) | POLB | |
| SCHEMBL16941603 | 0.81 | PIK3CD (0.44) | POLBPIK3CDARG1ARG2 | |
| SCHEMBL13905851 | 0.81 | S1PR1 (0.48) | POLBS1PR5S1PR1MAPTS1PR3 | |
| SCHEMBL321619 | 0.79 | PIK3CD (0.50) | POLBS1PR5PIK3CD | |
| SCHEMBL13905850 | 0.79 | S1PR5 (0.42) | POLBS1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL12391370 | 0.78 | PIK3CD (0.45) | POLBS1PR5S1PR1PIK3CDARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1417190-B1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-10-22 | — | — | EP | claimed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | claimed |
| US-7115607-B2 | Substituted piperazinyl amides and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | claimed |
| EP-1417190-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgen Inc. (US) | 2004-05-12 | — | — | EP | claimed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | claimed |
| WO-2003009850-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC. (US) | 2003-02-06 | — | — | WO | claimed |
| EP-4234030-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022212769-A1 | COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 (S1P1), IMAGING OF S1P1, AND PROCESSES FOR PREPARATION THEREOF | WASHINGTON UNIVERSITY (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20210024494-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10774071-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200207726-A1 | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2020-07-02 | — | — | US | disclosed |
| US-10676467-B2 | Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200017471-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-01-16 | — | — | US | disclosed |
| US-20190002450-A1 | COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 (S1P1), IMAGING OF S1P1, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2019-01-03 | — | — | US | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2009032326-A1 | NEW TETRACYCLINE DERIVATIVES AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-03-12 | — | — | WO | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774071-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | POLB 486/4885S1PR5 3075/4885S1PR1 1983/4885 |
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | POLB 2338/4885S1PR5 184/4885S1PR1 427/4885 |
| US-20110207704-A1 | Novel Oxadiazole Compounds | S1PR3, S1PR1, S1PR2 | POLB 4331/4885S1PR5 4/4885S1PR1 2/4885 |
| US-20200207726-A1 | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | RORA, RORC, RORB | POLB 4324/4885S1PR5 655/4885S1PR1 748/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | POLB 2338/4885S1PR5 184/4885S1PR1 427/4885 |
| US-20190002450-A1 | COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 (S1P1), IMAGING OF S1P1, AND METHODS OF USE THEREOF | S1PR1, S1PR2, S1PR3 | POLB 3855/4885S1PR5 4/4885S1PR1 1/4885 |
| US-20200017471-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | POLB 486/4885S1PR5 3075/4885S1PR1 1983/4885 |
| US-20080280876-A1 | Novel oxadiazole compounds | S1PR3, S1PR1, S1PR2 | POLB 4331/4885S1PR5 4/4885S1PR1 2/4885 |
| US-10676467-B2 | Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof | S1PR1, S1PR2, S1PR3 | POLB 3855/4885S1PR5 4/4885S1PR1 1/4885 |
| US-20210024494-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | POLB 486/4885S1PR5 3075/4885S1PR1 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.